Literature DB >> 18094193

Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus.

Elaine M Castilow1, Matthew R Olson, David K Meyerholz, Steven M Varga.   

Abstract

Secondary exposure to respiratory syncytial virus (RSV) can lead to immunopathology and enhanced disease in vaccinated individuals. Vaccination with individual RSV proteins influences the type of secondary RSV-specific immune response that develops upon challenge RSV infection, as well as the extent of immunopathology. RSV-specific memory CD4 T cells can directly contribute to immunopathology through their cytokine production. Immunization of BALB/c mice with a recombinant vaccinia virus (vv) expressing the attachment (G) protein of RSV results in pulmonary eosinophilia upon RSV challenge, whereas immunization of mice with a vv expressing the fusion (F) protein does not. We analyzed the CD4 T-cell response to an I-E(d)-restricted CD4 T-cell epitope within the F protein of RSV corresponding to amino acids 51 to 66 in an effort to better understand the similarities and differences in the immune response elicited by the G versus the F protein. Vaccination with the G protein induces a mixture of RSV G-specific Th1 and Th2 cells with a restricted T-cell receptor repertoire. In contrast, we demonstrate here that immunization with the F protein elicits a broad repertoire of RSV F-specific CD4 T cells that predominantly exhibit a Th1 phenotype. However, in the absence of gamma interferon (IFN-gamma), RSV F(51-66)-specific CD4 T cells secreted interleukin-5, and mice developed pulmonary eosinophilia after RSV challenge. IFN-gamma-deficient mice exhibited decreased weight loss compared to wild-type controls, suggesting that IFN-gamma exacerbates systemic disease. These data demonstrate that IFN-gamma can have both beneficial and detrimental effects during a secondary RSV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094193      PMCID: PMC2258940          DOI: 10.1128/JVI.01949-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope.

Authors:  J M Robertson; P E Jensen; B D Evavold
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  CD4(+) T cell frequencies and Th1/Th2 cytokine patterns expressed in the acute and memory response to respiratory syncytial virus I-E(d)-restricted peptides.

Authors:  R A Tripp; S Hou; N Etchart; A Prinz; D Moore; J Winter; L J Anderson
Journal:  Cell Immunol       Date:  2001-01-10       Impact factor: 4.868

3.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

4.  Visualization and characterization of respiratory syncytial virus F-specific CD8(+) T cells during experimental virus infection.

Authors:  J Chang; A Srikiatkhachorn; T J Braciale
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice.

Authors:  S M van Schaik; N Obot; G Enhorning; K Hintz; K Gross; G E Hancock; A M Stack; R C Welliver
Journal:  J Med Virol       Date:  2000-10       Impact factor: 2.327

6.  Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

Authors:  D K Shay; R C Holman; G E Roosevelt; M J Clarke; L J Anderson
Journal:  J Infect Dis       Date:  2000-11-10       Impact factor: 5.226

7.  The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.

Authors:  S M Varga; E L Wissinger; T J Braciale
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

8.  Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology.

Authors:  G Walzl; S Matthews; S Kendall; J C Gutierrez-Ramos; A J Coyle; P J Openshaw; T Hussell
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

9.  Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology.

Authors:  G Walzl; S Tafuro; P Moss; P J Openshaw; T Hussell
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

10.  Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.

Authors:  A Srikiatkhachorn; T J Braciale
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

View more
  32 in total

1.  Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Authors:  Ruihong Zeng; Huixian Zhang; Yan Hai; Yuxiu Cui; Lin Wei; Na Li; Jianxun Liu; Caixia Li; Ying Liu
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Authors:  Lydia Tan; Frank E J Coenjaerts; Lieselot Houspie; Marco C Viveen; Grada M van Bleek; Emmanuel J H J Wiertz; Darren P Martin; Philippe Lemey
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

3.  Intestinal IFN-γ production is associated with protection from clinical signs, but not with elimination of worms, in Echinostoma caproni infected-mice.

Authors:  Alba Cortes; Javier Sotillo; Carla Muñoz-Antoli; Bernard Fried; J-Guillermo Esteban; Rafael Toledo
Journal:  Parasitol Res       Date:  2014-03-16       Impact factor: 2.289

4.  Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms.

Authors:  John R Teijaro; David Verhoeven; Carly A Page; Damian Turner; Donna L Farber
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.

Authors:  Na Li; Ling Zhang; Boyang Zheng; Wenjian Li; Jianxun Liu; Huixian Zhang; Ruihong Zeng
Journal:  Hum Vaccin Immunother       Date:  2019-04-29       Impact factor: 3.452

6.  Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.

Authors:  Young-Man Kwon; Hye Suk Hwang; Jong Seok Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Jae-Min Song; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

7.  Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease.

Authors:  Elaine M Castilow; Kevin L Legge; Steven M Varga
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model.

Authors:  David K Meyerholz; Michelle A Griffin; Elaine M Castilow; Steven M Varga
Journal:  Toxicol Pathol       Date:  2009-01-29       Impact factor: 1.902

9.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

10.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.